Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana
Recruitment status was Recruiting
In areas of Africa where malaria is only a problem during a short rainy season, monthly courses of antimalarial drugs can provide very effective prevention of malaria in children. This approach, called intermittent preventive treatment in children (IPTc) but now known as Seasonal Malaria Chemoprevention (SMC), may also be useful in large areas of Africa where malaria is transmitted for longer each year. It is uncertain if IPTc would be effective, acceptable to communities or sustainable when delivered over a longer period, but this is an important public health question of key interest to policy makers, because in areas with a longer transmission season, the burden of malaria is typically higher than in highly seasonal areas.
Another form of prevention that would be operationally easier for African countries to put into practice would be to treat malaria patients with long-lasting antimalarials, which protect children against further malaria episodes for several weeks. Because malaria disproportionately affects certain high risk children more than others, causing repeated attacks of fever and leading to severe anaemia, long-acting drugs may be a simple and effective way to target limited resources at the individuals who most need protection. This may be particularly beneficial where malaria is a seasonal problem, because repeated malaria attacks will not only be borne by a few unfortunate children, but will also occur close together in time.
The investigators propose a clinical trial to evaluate these two forms of chemoprevention in Kumasi, Ghana, an area with an extended malaria transmission season. Children under 5 years of age currently have access to diagnosis and treatment of malaria via by community based health workers. Children enrolled in the study will receive either the standard community-based diagnosis and treatment, treatment with a longer-acting artemisinin combination therapy (ACT), or standard care plus five monthly courses of seasonal malaria chemoprevention (SMC) during the peak in transmission.
Drug: Artemether-lumefantrine combination
Drug: Dihydroartemisinin Piperaquine combination
Drug: Amodiaquine plus sulphadoxine-pyrimethamine combination
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana.|
- Incidence of malaria cases [ Time Frame: 12 months ] [ Designated as safety issue: No ]Incidence of malaria cases recorded by the community health workers (CHWs) and at the study health centres. Malaria will be defined as fever or history of fever combined with parasitologically confirmed P. falciparum infection by blood slide. Management of suspected malaria cases reporting to CHWs and health centres will be according to rapid diagnostic test (RDT).
- Proportion of children with parasitaemia [ Time Frame: 12 months ] [ Designated as safety issue: No ]Parasitaemia detected by rapid diagnostic test (RDT) and parasitologically confirmation of P. falciparum infection by blood slide..
- Proportion of children with anaemia [ Time Frame: 12 months ] [ Designated as safety issue: No ]Anaemia is defined as haemoglobin less than <8 g/dL
- Number of referrals [ Time Frame: 12 months ] [ Designated as safety issue: No ]Referrals to hospital and admissions due to malaria and other causes
- Incidence of severe illness [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Incidence of adverse events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Acceptability of seasonal malaria chemoprevention [ Time Frame: 2 months ] [ Designated as safety issue: No ]Acceptability of seasonal malaria chemoprevention through Focus Group Discussions and in-depth interviews
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||April 2013|
|Estimated Primary Completion Date:||December 2012 (Final data collection date for primary outcome measure)|
Active Comparator: HMM using short-acting ACT
Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
|Drug: Artemether-lumefantrine combination|
Experimental: HMM using short-acting ACT plus SMC
Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
|Drug: Artemether-lumefantrine combination Drug: Amodiaquine plus sulphadoxine-pyrimethamine combination|
Experimental: HMM using a long-acting ACT
Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
Drug: Dihydroartemisinin Piperaquine combination
Other Name: Duo-cotecxin
Please refer to this study by its ClinicalTrials.gov identifier: NCT01651416
|Contact: Harry Tagbor, DrPHemail@example.com|
|Contact: Gifty D Antwi, MPHfirstname.lastname@example.org|
|Kumasi, Ashanti, Ghana|
|Contact: Gifty D Antwi, MPH +233244596229 email@example.com|
|Contact: Ruhama P Mahama, MPH +233265212568|
|Sub-Investigator: Ruhama P Mahama, MPH|
|Principal Investigator:||Harry Tagbor, DrPH||Kwame Nkrumah University of Science and Technology|